Physician profile
Michael D Brottman
NPI 1609820919
$2,391.67
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $113 · 2021: $72.78 · 2022: $494 · 2023: $392 · 2024: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $524.92 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $443.58 | 2019-2022 | |
| Pfizer INC. | $261.12 | 2019-2024 | |
| Amgen INC. | $176.14 | 2019-2022 | |
| Heartflow, INC. | $155.60 | 2019-2024 | |
| Abbott Laboratories | $144.59 | 2022-2023 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.79 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $120.15 | 2023-2024 | Camzyos, Eliquis |
| Boston Scientific Corporation | $110.70 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $67.89 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.30 | 2019-2020 | |
| Novo Nordisk INC | $47.96 | 2024 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $46.19 | 2022-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $34.02 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $30.07 | 2024 | Arcalyst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $18.52 | 2024 | |
| Medtronic, INC. | $13.88 | 2024 | Venaseal |
| Chiesi USA, INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brottman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.